CD274 and neoplasm: PD-L1 is very commonly expressed in ENTKL in 56–80% of cases [86,87], with the interplay of PD-1 and PD-L1 in the TME of particular interest in the therapeutic targeting of ENKTL, with a study finding that PD-L1 is expressed on both tumor cells as well as tumor-infiltrating macrophages in the ENKTL TME, suggesting that ENKTL cells may additionally induce immunosuppression by upregulation of PD-L1 in macrophages [88].